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JThis paper focuses on the relationships among the U.S. Preventive Services Task Force (USPSTF);
Agency for Healthcare Research and Quality (AHRQ); and NIH. After a brief description of the Task
Force, AHRQ, NIH, and an example of how they interact, we describe the steps that have been taken
recently by NIH to enhance their coordination. We also discuss several challenges that remain and
consider potential remedies that NIH, AHRQ, and investigators can take to provide the USPSTF with
the data it needs to make recommendations, particularly those pertaining to behavioral interventions.
(Am J Prev Med 2015;49(3S2):S166–S173) Published by Elsevier Inc. on behalf of American Journal of
Preventive Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionThe papers in this Special Issue describe the U.S.Preventive Services Task Force (USPSTF) and itsrole in evaluating evidence relevant to preventive
services. The USPSTF interfaces with the Agency for
Healthcare Research and Quality (AHRQ) and NIH, and
this article describes their relationships. This article also
highlights some of the challenges of merging evidence-
based traditions across disciplines. It includes speciﬁc
suggestions for steps that NIH, AHRQ, and the research
community can take to provide better evidence for use by
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This is an open access article under the CC BY-NCThe U.S. Preventive Services Task Force
TheUSPSTF is an independent, volunteer panel of national
experts in disease prevention and evidence-basedmedicine;
it is composed of primary care providers such as internists,
pediatricians, family physicians, gynecologists/obstetri-
cians, nurses, and health behavior specialists. The USPSTF
commissions systematic evidence reviews that examine the
existing body of research on preventive services to be
provided by primary care clinicians or referred from
primary care. The USPSTF uses these reviews as the basis
for its recommendations, carefully assessing the evidence on
the beneﬁts and harms of screening tests, counseling about
healthful behaviors, and preventivemedications for children,
adolescents, adults, older adults, and pregnant women. The
USPSTF does not formally consider cost in its evaluations.
By examining both potential beneﬁts and harms, the
USPSTF makes recommendations that help clinicians
and patients make informed, individualized choices
based on the best available data.
The primary audience for the USPSTF’s work is the
primary care clinician. USPSTF recommendations are now
considered by many to provide deﬁnitive standards for
preventive services. In addition, the work of the USPSTF is
recognized by the Patient Protection andAffordable Care Act;
preventive services with a grade of A or B (www.uspreventi
veservicestaskforce.org/Page/Name/grade-deﬁnitions) must
be covered without cost sharing (e.g., copayment or deduc-
tible) under new health insurance plans or policies.1sevier Inc. on behalf of American Journal of Preventive Medicine.
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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AHRQ. AHRQ staff provide support for the USPSTF’s
activities.The Agency for Healthcare Research and Quality
The mission of AHRQ is to produce evidence to make
health care safer, higher quality, more accessible, equi-
table, and affordable, and to work within the USDHHS
and with other partners to make sure that the evidence is
understood and used. AHRQ supports the USPSTF
through the work of its staff and Evidence-based Practice
Centers that prepare the evidence reviews for the
USPSTF. In turn, the work of the USPSTF addresses
the mission of AHRQ by issuing recommendations to
make health care safer; of higher quality; and more
accessible, equitable, and affordable. The recommenda-
tions of the USPSTF, which are updated every 5 years,
provide evidence that will improve healthcare afford-
ability, efﬁciency, and cost transparency.The NIH
The mission of the NIH is to seek fundamental knowl-
edge about the nature and behavior of living systems andFigure 1. U.S. Preventive Services Task Force analytic framewor
in primary care to reduce alcohol misuse.
Source: Jonas DE, Garbutt JC, Brown JM, et al. Screening, Behavioral Counsel
Effectiveness Review No. 64. AHRQ Publication No. 12-EHC055-EF. Rockvill
Note: KQ 1–6 refer to key questions addressed by this framework.
September 2015the application of that knowledge to enhance health,
lengthen life, and reduce illness and disability. According
to NIH Research, Condition, and Disease Categorization
data (report.nih.gov/rcdc/), NIH support for prevention
research in 2013 was estimated to be about 22% of the
total NIH expenditures. Yet, even with this substantial
investment, important gaps remain and are identiﬁed in
the Evidence-based Practice Centers and by the USPSTF.
These gaps prevent the USPSTF from making clear
recommendations for all of the preventive services that
it reviews. This is one of the primary reasons to enhance
the coordination among the NIH, AHRQ, and USPSTF.An Example
An example of how the USPSTF, working through
AHRQ, uses NIH-funded research is found in its
recommendation statement “Screening and Behavioral
Counseling in Primary Care to Reduce Alcohol Misuse”
(www.uspreventiveservicestaskforce.org/Page/Document/
evidence-summary9/alcohol-misuse-screening-and-beha
vioral-counseling-interventions-in-primary-care). When
reviewing any topic, the USPSTF ﬁrst develops a research
plan with an Analytic Framework and Key Questions, ask and key questions for screening and behavioral counseling
ing, and Referral in Primary Care to Reduce Alcohol Misuse. Comparative
e, MD: Agency for Healthcare Research and Quality; 2012.
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Evidence-based Practice Center searches PubMed,
Cochrane, and other databases for RCTs, observational
studies, and review articles, with prespeciﬁed inclusion/
exclusion criteria for each question. The USPSTF deter-
mines whether the available evidence for each key ques-
tion is “inadequate,” “adequate,” or “convincing.” In this
example, the USPSTF determined that the evidence for the
beneﬁts (Key Question 1) and harms (Key Question 3) of
screening were inadequate (Table 1). Even so, the USPSTF
still gave a “B” recommendation reﬂecting the USPSTF
assessment that there is moderate certainty of moderate
net beneﬁt. This determination was based on adequate
evidence on the detection of the condition (Key Question
2) and beneﬁts of interventions (Key Questions 4 and 6).
In this example, the evidence for the beneﬁts of counseling
and intervention came from NIH-funded research.
NIH Steps to Enhance Coordination With
the U.S. Preventive Services Task Force
The NIH established the Ofﬁce of Disease Prevention
(ODP) in 1986 to provide leadership for the develop-
ment, coordination, and implementation of prevention
research in collaboration with NIH Institutes and Cen-
ters (ICs) and other Federal partners. The ODP serves as
the NIH liaison to the USPSTF, attending USPSTF
meetings and providing updates to the NIH Director as
needed. With the arrival of a new Director (DMM) inTable 1. Evidence in Screening and Counseling Alcohol Misuse
Key questions
Assessment of
evidence
1. Direct evidence of screening beneﬁt Inadequate
2. Detection Adequate A
s
4/6. Beneﬁts of brief behavioral counseling
Intermediate outcomes: Adequate M
 Reduced consumption (drinks/week)
 No binge drinking
 Attainment of recommended
drinking levels
Healthcare utilization (no. of hospital
days)
Adequate M
Morbidity (alcohol-related accidents or
liver problems)
Inadequate
Mortality Inadequate
3/5. Harms of screening and treatment Inadequate C
tSeptember 2012, the ODP reviewed its work as the NIH
USPSTF liaison to consider opportunities to enhance the
coordination between the NIH and the USPSTF and
identiﬁed seven areas for enhanced coordination:1.M
cce
pe
od
od
an
hannomination of new USPSTF members;
2. nomination of new topics or topics to revisit;
3. comments on proposed topics and topic prioritization;
4. comments on proposed research plans;
5. comments on draft evidence reports and clinical
recommendations;
6. comments on ﬁnal evidence reports, clinical recom-
mendations, and messaging; and
7. communicating insufﬁcient evidence statements to
the NIH research community.
ODP then developed steps it could take to address
these areas and presented that plan to the NIH Director
and the IC Directors in August 2013.
After the NIH leadership had endorsed the plan, the
ODP asked each IC Director to identify a liaison for
USPSTF activities who was familiar with activities relevant
to the USPSTF and had authority to make assignments to
other staff. IC Directors often named their Deputy Director
or a Division Director as the liaison. Those liaisons were
asked to identify primary and secondary content experts
for each current and previous USPSTF topic that was of
interest to their IC. They were also asked to identify primary
and secondary communications staff who would be ableagnitude of effect
ptable sensitivity/
ciﬁcity
erate
erate
bound as no greater
smallto review and comment on
USPSTF announcements.
In November 2013, the
ODP convened a meeting of
the USPSTF liaisons from the
ICs to review the plan to
improve coordination. The
USPSTF Scientiﬁc Director
(QNM) gave an overview of
the USPSTF activities, and
ODP staff described the plan,
presented below.
In January of each year,
the ODP will ask the
IC liaisons to nominate new
members for the USPSTF, to
provide suggestions for new
topics and existing topics to
be revisited. ODP will share
this input with the AHRQ.
Once the USPSTF identi-
ﬁes a preliminary list of
topics, the ODP will ask the
IC liaisons and contentwww.ajpmonline.org
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prioritization. The IC content experts also will be asked
to comment on which proposed topics might beneﬁt
from a delay. Those experts might know, for example,
that a major study with important implications for a
topic would be completed in another year, so that it
would make more sense to delay the review.
Once AHRQ releases the draft research plan for each
topic, the ODP will ask the IC content experts for
comments. As AHRQ implements the research plan,
the ODP will work with IC content experts to identify
new research developments that may be relevant and
share them with AHRQ.
The ODP will alert IC liaisons and content experts
once a schedule is set for the release of a preliminary
evidence report. This version is not released to the public
but is shared with the USPSTF’s federal partners to allow
them to provide feedback while the report is being
developed. The ODP staff will share the NIH feedback
with AHRQ. NIH content expert reviews help to ensure
that all the relevant literature has been included and
interpreted correctly.
The ODP will alert IC liaisons and content experts once a
schedule is set for the release of a draft evidence report and
recommendation, together with any press release prepared
by the USPSTF. These materials are released for public
comment. The ODP typically receives the material 1 week
before public release and will share it with the appropriate
ICs so that they may identify a staff member to respond to
press inquiries. As appropriate, the ODP will also alert
senior NIH leadership. The ODP will send suggestions on
the press release to AHRQ. When the draft evidence report
and recommendation are released to the public, the ODP
will post links to the documents on its website.
The ODP will follow the same procedures for the ﬁnal
evidence reports and recommendations, together with
any press releases prepared by the USPSTF.
The ODP will review ﬁnal evidence reports and
insufﬁcient evidence statements to identify research gaps
and share those with the relevant ICs. The ODP will also
ask IC liaisons to report annually on their activities
planned or in place that address those research gaps. The
goal will be to identify areas in which NIH is not doing
enough to address the insufﬁcient evidence statements
and then work with the ICs to try to do more. This could
happen, for example, by collaborating with multiple ICs
to develop cooperative Funding Opportunity Announce-
ments (FOAs) to address those areas, whether in the
form of new grants or as supplements to existing grants.
The ODP has created a tracking system to monitor the
progress of active topics and to monitor the research
portfolios of the ICs that are relevant to insufﬁcient
evidence statements.September 2015NIH Steps to Enhance the Evidence Base
for Behavioral Counseling Interventions
Behavioral counseling interventions often lack the evi-
dence to allow the USPSTF to fully evaluate the inter-
vention and make a clear recommendation.2 This results
in an “insufﬁcient,” or I, statement for those interven-
tions. In an effort to determine whether ICs are devel-
oping the needed evidence, the ODP queried several ICs
that support behavioral counseling interventions in
August 2014 on their activities in six speciﬁc areas
identiﬁed by the USPSTF as challenges in these inter-
vention studies. This section summarizes their responses.
Risk Stratiﬁcation
The USPSTF needs evidence on the effects of the inter-
vention according to the symptoms or risk status of the
participants. However, there is often no consensus among
investigators for reporting outcomes stratiﬁed in this way.
None of the responding ICs had initiated activities to
develop a consensus in this area, so this is an area where
ODP may be able to work with the ICs to address this issue.
In addition, it may be helpful for others, such as professional
societies, to lead the effort to develop that consensus.
Feasibility of Referral From Primary Care
The USPSTF needs evidence on the feasibility of referral
from primary care to a behavioral counseling interven-
tion that is delivered in some other clinical or community
setting. A number of the ICs are supporting projects in
this area. For example, the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) has funded
research based on the Diabetes Prevention Program3,4 to
screen for prediabetes in primary care and refer to a
lifestyle intervention delivered in community settings
such as the YMCA5 or by community health workers.6
The National Institute on Drug Abuse (NIDA) is
supporting two studies that are examining screening for
substance use risk and referral through primary care
either to a community-based or online intervention.
NIDA is also supporting a study to test an intervention
to improve primary care provider compliance with
chronic opioid therapy guidelines to reduce opioid
misuse among patients; a component of the intervention
is assessment and referral to substance abuse treatment.
The National Institute for Mental Health (NIMH) is
supporting a study that screens adolescents for depres-
sion risk in primary care and refers those at risk to an
Internet-based depression prevention intervention.
Dose and Component Effects
The USPSTF needs evidence on the dose of the inter-
vention used in behavioral counseling studies as well as
2015;49(3S2):S166–S173 S169
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components in multicomponent interventions. However,
there is often no consensus for how to measure the dose
of the intervention or how to assess the relative con-
tribution of speciﬁc components. None of the responding
ICs had initiated activities to develop a consensus in this
area, so this is another area where ODP may be able to
work with ICs to address this issue. In addition,
professional societies may be able to help here, by leading
discussions appropriate to their areas of interest.Adverse Events
The USPSTF needs evidence for adverse events that may
result from behavioral counseling studies so that it can
fully evaluate potential harm. NIH does require admin-
istrative reporting of adverse events in all of its clinical
trials, including those evaluating behavioral counseling
interventions. One limitation appears to be the lack of
consensus on reporting this information in published
reports of study outcomes. NIH cannot require such
reporting, but professional societies may be able to help
by leading discussions appropriate to their areas of
interest. Transparent reporting standards, such as
CONSORT,7,8 can help by requiring reports of adverse
events.Standardization of Measures
One of the barriers to pooling evidence across studies is
the lack of standardization of behavioral measures often
used as outcomes. NIH supports a number of activities
to help develop standardized measures. The National
Cancer Institute (NCI) supports the Grid-Enabled Meas-
ures Program, an interactive web-based portal that
enables consensus on the standardization of behavioral
measures and theories used in behavioral counseling
intervention studies. It includes constructs in distress
measurement, care planning, and shared decision mak-
ing in the clinical setting. In addition, many of the ICs
support the PhenX toolkit project.9 Begun by the
National Human Genome Research Institute, the toolkit
project is developing standard measures in a variety of
areas, including anthropometrics (National Institute of
Child Health and Human Development [NICHD];
National Institute of Aging [NIA]); alcohol, tobacco,
and other substance abuse (NIDA, NCI, National Insti-
tute of Alcohol Abuse and Alcoholism [NIAAA]); cancer
(NCI); cardiovascular disease (National Heart Lung and
Blood Institute [NHLBI]); diabetes (NIDDK); environ-
mental exposures (National Institute of Environmental
Health Sciences); infectious disease (National Institute of
Allergy and Infectious Diseases [NIAID]); nutrition(Ofﬁce of Dietary Supplements); oral health (National
Institute of Dental and Craniofacial Research); physical
activity and ﬁtness (NCI, NIDDK); psychiatric (NIMH),
psychosocial (NCI), and reproductive health (NICHD);
respiratory ailments (NHLBI, NIAID); skin, bone, and
muscle diseases (National Institute of Arthritis and
Musculoskeletal and Skin Diseases, NIA); social environ-
ments (NIDA, NIAAA); and speech and hearing impair-
ment (National Institute on Deafness and Other
Communication Disorders).
In addition, the Ofﬁce of Behavioral and Social
Sciences Research in collaboration with CDC, the Cen-
ters for Medicare and Medicaid Services, the Robert
Wood Johnson Foundation, and the Pritzker Traubert
Family Foundation funded an IOM Report that recom-
mended harmonized psychosocial and behavioral meas-
ures for inclusion in the electronic health record.10 The
IOM committee evaluated the association between the
domains and health outcomes and considered the value
of information in each domain for clinical decision
making, population monitoring, and health policy for
clinical and public health research, reliability and val-
idity, response burden, and the sensitivity of the
requested information. Based on these criteria, the
committee recommended a dozen measures for routine
capture in the electronic health record:1. tobacco use;
2. alcohol use;
3. race/ethnicity;
4. place of residence;
5. education level;
6. ﬁnancial resource strain;
7. stress;
8. depression;
9. physical activity;
10. social isolation;
11. intimate partner violence; and
12. neighborhood median household income obtained
from residence.The NIH has also developed a set of harmonized
measures for the assessment of neurologic function and
behavior. Their publically available NIH Toolbox for
Assessment of Neurological and Behavioral Function is
an integrated set of tools for measuring cognitive, emo-
tional, motor, and sensory function. These tools have
been validated for use in diverse cultures, ethnic and
geographic groups, and ages (3–85 years). Measures in
the toolbox are low-cost and royalty-free, use computer-
adaptive testing, and are available in English and
Spanish.www.ajpmonline.org
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The USPSTF needs evidence linking behavioral out-
comes from behavioral counseling interventions to
health outcomes or intermediate biometric risk factors.
This is a particular challenge because of the time lags that
often exist between behavior change and change in
biometric risk factors or health outcomes. In addition,
studies powered to detect differences in health behaviors
are rarely powered to detect differences in health out-
comes or biometric risk factors. Even so, several of the
ICs support projects that link behavioral outcomes from
behavioral counseling interventions to health outcomes
or intermediate biometric risk factors. For example,
NIDDK requires inclusion of biometric risk factors
(e.g., glycosylated hemoglobin, weight change expressed
as BMI, percentage weight or body fat decrease, diabetes
risk factor control) in a number of its funding oppor-
tunity announcements.Discussion
There are many compelling reasons to coordinate the
activities of the USPSTF, AHRQ, and NIH with respect
to preventive services including behavioral counseling
interventions. The USPSTF needs access to all available
evidence as it develops its recommendations, and that
evidence often comes from research supported by the
NIH. The NIH needs to identify gaps in the evidence and
the USPSTF’s evidence reviews, and recommendation
statements regularly do that. AHRQ has a strong interest
in supporting coordination in order to comply with its
mandate to support the USPSTF and AHRQ’s mission to
develop evidence to make health care safer; of higher
quality; and more accessible, equitable, and affordable
and to make sure that the evidence is understood
and used.
Even so, barriers remain that often make it difﬁcult for
the USPSTF to issue clear recommendations.2 Some of
these are a function of the differences between the foci of
the USPSTF, AHRQ, and NIH, whereas others stem from
a lack of consensus among investigators.Primary Care Versus Other Settings
The USPSTF focuses on preventive services that can be
linked to primary care, which can eliminate some
preventive services from consideration. For example, a
primary care provider cannot refer a child to a school-
based intervention that is not offered in that child’s
school. Similarly, a primary care provider cannot refer an
adult patient to a church, worksite, or other community
intervention if that organization and intervention are not
available for that patient.September 2015Asymptomatic Versus Symptomatic Populations
The USPSTF focuses on the beneﬁts of interventions for
people who are asymptomatic, though it also considers
evidence from studies conducted in symptomatic, diag-
nosed patients. Although the latter is included, for
example, in the reviews of treatment beneﬁts and harms,
the USPSTF puts more weight on studies of treatment
delivered to patients whose condition is detected through
screening.Rigor of Study Design
The USPSTF exercises very high standards for what is
included in the systematic reviews conducted by AHRQ’s
Evidence-based Practice Centers. The USPSTF considers
a wide range of evidence and discussions take study
design into consideration. RCTs are given the greatest
weight because they maximize internal validity and are
clearly the best tool for supporting causation. At the same
time, RCTs testing efﬁcacy often have poor external
validity.2,11 NIH and AHRQ are exploring alternatives to
RCTs, including pragmatic or practical clinical trials and
a variety of methods that use “big data.” We are also
seeing increased interest in the multiphase optimization
strategy,12 in sequential multiple assignment randomized
trial13 designs, and in other innovative approaches to
evaluating preventive interventions (e.g., www.nihorbit.
org/ORBIT%20Content/Workshops%20and%20Conferences.
aspx?PageView=Shared). As these methods are vali-
dated, we expect greater acceptance by the academic
communities. With peer acceptance, alternative methods
may have a greater role in USPSTF evaluations.
Another concern has been standards for reporting
research results. Some observers suggest that behavioral
trials have not always employed the same level of
transparent reporting seen in drug or surgical trials.14
For example, behavioral trials have been slower to adopt
conventions such as intention-to-treat analyses and use
of CONSORT diagrams has been less common in
behavioral trials.Outcome Measures
There is a growing recognition that clinical indicator
measures cannot always be substituted for health out-
comes. For example, we encourage exercise among
people with type 2 diabetes because it may result in
reductions in glycosylated hemoglobin; however, gly-
cosylated hemoglobin is not a health outcome. The
Action to Control Cardiovascular Risk in Diabetes trial
demonstrated that aggressive management of blood
glucose did not result in the expected reduction in
cardiovascular deaths15,16; in fact, there was an increase
in all-cause mortality among patients experiencing
Murray et al / Am J Prev Med 2015;49(3S2):S166–S173S172aggressive blood glucose control. The message that we
cannot substitute clinical indicators for health out-
comes is well accepted in the clinical trials community,
yet this strategy has not made its way to the behavioral
research community, and more behavioral trials could
include health outcomes such as type 2 diabetes,
coronary artery disease, or obesity. Investigators typi-
cally assume that a trial is successful if it has an effect
on an intermediate outcome such as a targeted health
behavior, although ultimately the impact of an efﬁca-
cious intervention trial should lead to changes in health
outcomes in order to support USPSTF recommenda-
tions. This also has implications for NIH, as the ICs will
have to fund the research to evaluate behavioral
interventions that address health outcomes, not just
behavioral outcomes. NIH will also have to fund studies
with long enough follow-up for health outcomes to
satisfy the USPSTF that the behavioral interventions
can have a durable effect that warrants an A or B
recommendation.Conclusions
In spite of the differences in their missions and foci, the
USPSTF, AHRQ, and NIH complement and support
each other to improve the health of the nation. The
steps taken recently by the ODP, if fully implemented,
will improve their coordination. For example, ODP will
work actively with the NIH ICs to ensure that the
USPSTF has access to the most up-to-date information
about recent and ongoing studies supported by those
ICs. ODP also will work actively with the ICs to explore
opportunities to support new research to address
insufﬁcient evidence statements. Finally, NIH will
continue to support efforts to standardize measures to
make it easier for the USPSTF to compare ﬁndings
across studies.
Even with these steps by NIH, additional steps will be
required of others in order for the USPSTF to have all of
the evidence it needs to make clear recommendations.
Researchers need to provide evidence on the effects of
their intervention according to the symptoms or risk
status of the participants, on the feasibility of referral
from primary care for their behavioral intervention, on
the dose of the intervention and the relative contribution
of speciﬁc components, on adverse events, and on the
effects of their behavioral interventions on health out-
comes in order to provide the kind of evidence that the
USPSTF needs. Professional societies may be in a good
position to play a helpful role with respect to encouraging
reporting of outcomes stratiﬁed by symptoms or risk
status, reporting of dose and the effects of individualcomponents of multicomponent interventions, and
reporting adverse events in publications they sponsor
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